Clinical Trial Update: Effect of Diltiazem Administration on CP-945,598 Pharmacokinetics [Phase 1]

View source ↗

Summary

Phase 1 study evaluated the effect of diltiazem on the pharmacokinetics of the investigational compound CP-945,598 in obesity; the trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• CP-945,598 (CP-945,598)
• Diltiazem (diltiazem)

Snippet

Sponsor: Pfizer | Conditions: Obesity | Phase 1 | Status: COMPLETED